Protagenic Therapeutics (PTIX) announced that warrant exchanges and exercises over the last four trading days have generated $3.1M in cash. The proceeds will fund working-capital needs and advance the Company’s peptide-based drug candidates for stress-related and central-nervous-system disorders.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTIX:
- Protagenic Therapeutics Issues Common Stock for Warrants
- Protagenic Therapeutics Completes Acquisition of Phytanix Bio
- Protagenic Therapeutics, Phytanix Bio to combine in all-stock transaction
- Protagenic Therapeutics, Phytanix Bio enter business combination agreement
- Biotech Alert: Searches spiking for these stocks today